Navigation Links
Pharma and Biotech Leaders to Converge in Shanghai
Date:11/9/2009

SHANGHAI, Nov. 9 /PRNewswire-Asia/ -- The pharma and biotech sectors are at a pivotal point in their evolution. The companies are facing significant pressure to change with thinning pipelines, skyrocketing R&D costs, calls for lower prices and a greater regulatory burden, these conditions together with the financial crisis have made the work of creating new drugs harder than ever. Big pharmaceutical companies are being forced to globalize their R&D operations, especially to emerging markets.

Under this background, leaders of pharma and biotech companies from around the world will gather in Shanghai on March 4-5, 2010 at Asia Pharma R&D Leaders 2010 for strategies to capitalize on the enormous opportunity the booming Asia Market provides.

This event focuses on the operational, regulatory, and strategic challenges of outsourcing your drug discovery work to Asia.

Hear from distinguished industry experts at Asia Pharma R&D Leaders 2010. Some of this year's highlighted topics include:

    -- Partnering for innovation in Asia, new collaboration opportunities with
       big pharma

       -- Laurent Bertin, Vice President, R&D External Innovation, Sanofi-
          Aventis
       -- Hans-Jochiam Bohm, Head of Global Chemistry, Hoffman La-Roche
       -- Daniel Grant, Head of Strategic Alliances, Pfizer Australia
       -- Pierre Desmons, Director, Head of Development Partnerships,
          GlaxoSmithKline Biologicals

    -- Regulatory updates in China and how FDA is making sure the quality of
       outsourced work

       -- Christopher Hickey, Country Director (China), U.S. Food and Drug
          Administration

    -- Successful stories of R&D operation management in Asia and Do's &
       Don'ts in outsourcing

       -- Steve Yang, Head of Research Asia Global R&D, Pfizer
       -- Lily Lee, Senior Vice President and Head of Pharmaceutical R&D Asia,
          Johnson and Johnson
       -- Li Chen, Chief Scientific Officer Roche R&D China
       -- Tony Zhang, Managing Director and Site Head of China, Eli Lilly
          Global R&D
       -- Samantha Du, CEO, Hutchison MediPharma
       -- Richard Wang, Director, Strategic Alliance and Collaboration for
          Asia, AstraZeneca
       -- Yoshiki Nishikawa, Director of Kobe Pharma Research Institute Nippon,
          Boehringer Ingelheim

Plus, the event sets up an effective platform for you to meet face to face with a variety of Asia's local CROs and leading clinical practitioners to discuss the specifics of your outsourcing requirements.

An international audience consisting of senior-level pharma and biotech executives from the R&D, clinical development, business development, global market access, licensing, and regulatory affairs functions will be in attendance. For the full program and list of companies scheduled to attend, please visit the event website at http://www.aprdl.com .

For more information on registration and sponsoring/exhibiting, please contact:

Daniel Chen

Tel: +86-21-3251-6110

Email: daniel.chen@globaleaders.com

SOURCE Global Leaders Institute


'/>"/>
SOURCE Global Leaders Institute
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th
2. Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference
3. DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix
4. Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference
5. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
6. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
8. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
9. Laureate Pharma Welcomes Three New Members to Business Development Team
10. Pharmasset to Webcast an Investor Event from the AASLD Meeting
11. ViroPharma to Present at Three November Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... NC (PRWEB) , ... January 16, 2017 , ... ... company, received the prestigious Tibbetts Award from the U.S. Small Business Administration. ... “that have created a significant economic or social impact […] and are considered the ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ranks the ... evaluates the patent estate of a company, its impact and significance, and the likelihood ... the way in technologies that transform energy sources such as low dose X-ray and ...
(Date:1/12/2017)... 12, 2017   Protein Sciences Corporation , ... Flublok Influenza Vaccine ®, announced today that ... good safety results and induced strong neutralizing antibodies ... product is expected to advance into human clinical ... the Institute of Technology in Immunobiologicals of the ...
Breaking Biology Technology:
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):